ACCESS Newswire
10 Jul 2025, 19:47 GMT+10
Dual siRNA Therapeutic Confirms Its Robust In Vivo Results, Strongly De-Risking the Clinical Path and Underscoring CCT-217's Potential as a Transformative, Patient-Friendly Therapy for Obesity and Metabolic Disorders
BOSTON, MASSACHUSETTS / ACCESS Newswire / July 10, 2025 / Canary Cure Therapeutics (Canary), a pioneering biopharmaceutical company, today announced groundbreaking human cell data for its lead therapeutic candidate, CCT-217. The findings confirm a unique mechanism that promotes rapid, selective fat loss while preserving and building muscle. This strong human and preclinical evidence de-risks the clinical path for a transformative, twice-yearly treatment for obesity, with Phase 1 trials targeted for 2026.
The global obesity market is projected to exceed $200 billion by 2031, yet current treatments primarily rely on appetite suppression, often leading to significant loss of healthy muscle. CCT-217 represents a paradigm shift by targeting the underlying metabolic causes of obesity.
'While weight loss can be achieved by decreasing calorie intake, we believe increasing the body's ability to burn fat - especially harmful visceral fat - is a fundamentally healthier approach,' said Raj Reddy, CEO of Canary. 'Our goal is to improve body composition and overall metabolic function.'
Developed from Canary's proprietary dual siRNA platform, CCT-217 is engineered to increase energy expenditure by converting energy-storing white fat into metabolically active, energy-burning beige fat.
Highlights From Recent Data:
Human Cell Data Confirms Mechanism: Recent studies on differentiated human white fat cells treated with CCT-217 showed a rapid and significant increase in key thermogenic gene markers within just 72 hours. This powerful result in human cells validates the therapy's core mechanism and potential efficacy, providing a clear path toward clinical trials.
Dramatic, Fat-Selective Weight Loss in Preclinical Models: In diet-induced obese (DIO) animal models, CCT-217 demonstrated remarkable results in only 20 days:
26% reduction in total body weight
60% reduction in harmful visceral fat
25% increase in lean muscle mass
Comprehensive Metabolic Health Improvements: Beyond weight loss, CCT-217 treatment led to a complete reversal of liver steatosis (fatty liver), a 20% reduction in cholesterol, and enhanced insulin sensitivity, underscoring its potential to address a wide range of obesity-related co-morbidities.
CCT-217 offers patient-friendly, twice-yearly subcutaneous injections, using a proven Lipid Nanoparticle (LNP) platform to target siRNA delivery to adipose tissue - an endocrine organ central to the development of metabolic diseases - while minimizing off-target effects. Canary's second asset, CCT-007, targets genes over-expressed in post-menopausal women for healthy weight loss with fewer side effects.
'The strong correlation between our new human cell data and the dramatic in vivo animal model outcomes provides critical de-risking evidence,' said Dr. Reddy. 'We are now focused on advancing CCT-217 into Phase 1 clinical trials in 2026 to bring this next-generation therapy to patients. We are fortunate to have exceptional advisors overseeing the clinical development including Dr. Michael Lincoff, Principal Investigator of the groundbreaking SELECT Trial.'
Canary is currently raising a Series A round of $25 million to advance CCT-217 into Phase 1 trials, expected to start in 2026.
About Canary Cure Therapeutics
Canary Cure Therapeutics is a late-stage preclinical biopharmaceutical company pioneering next-generation RNA therapeutics for obesity and metabolic disease. Its proprietary dual-siRNA platform is engineered to induce class-leading thermogenesis, offering a differentiated, muscle-sparing approach to weight loss and metabolic health.
Contact Information
Anna Wang
Chief Strategy Officer
[email protected]
+41 79 204 2875
SOURCE: Canary Cure Therapeutics
Get a daily dose of Caribbean Herald news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Caribbean Herald.
More InformationAMSTERDAM, Netherlands: Some 32 percent of global semiconductor production could face climate change-related copper supply disruptions...
NEW YORK, New York - U.S. stocks rebounded Tuesday with all the major indices gaining ground. Markets in the UK, Europe and Canada...
NEW YORK CITY, New York: Financial markets kicked off the week on a cautious note as President Donald Trump rolled out a fresh round...
RIO DE JANEIRO, Brazil: At a two-day summit over the weekend, the BRICS bloc of emerging economies issued a joint declaration condemning...
LONDON, U.K.: This week, BP appointed Simon Henry, former Shell finance chief, to its board as a non-executive director effective September...
OTTAWA, Canada: With Canada Post struggling to maintain operations amid labour unrest, rivals like FedEx and UPS are stepping in to...
Paris [France], July 10 (ANI): The UK will invest Euro 163.3 million in Paris-headquartered satellite communications company Eutelsat,...
Chennai (Tamil Nadu) [India], July 10 (ANI): Former Malaysian Member of Parliament Tan Sri Lim Kit Siang on Thursday criticised US...
Indonesia has said it is ready to face the consequences of being part of the economic bloc Indonesia will remain in BRICS even if...
New Delhi [India], July 10 (ANI): Ambassador of India to Argentina, Ajaneesh Kumar of the Indian Foreign Service (IFS) Batch of 1996,...
New Delhi [India], July 10 (ANI): BJP national spokesperson Sudhanshu Trivedi on Thursday said that Prime Minister Narendra Modi's...
(250710) -- ARLINGTON, July 10, 2025 (Xinhua) -- Ni Feifan (C) of China celebrates during the match between Dominican Republic and...